Collector Offers Flexibility and Capacity for Applications from Discovery to Scale Up
Hercules, CA — December 08, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the NGC Fraction Collector. When used with the NGC Chromatography System, the NGC Fraction Collector provides the flexibility and collection capacity needed for any application, from discovery to scale up.
The NGC Fraction Collector allows researchers to choose how to collect and when to access their fractions. The system can be triggered to collect based on slope, percent of buffer from pump B, pH, and detector signals. Front-to-back dispensing provides easy access to fractions before method completion for faster downstream analysis. Researchers can also choose the type of collection vessel they prefer for each phase in a method, including deep-well plates, tubes, bottles, and carboys (with prep-rack adaptors for large-scale purification). Adding two new fraction collectors to each NGC System can further expand capacity.
A highly efficient benchtop Peltier cooling module saves lab space and preserves the integrity of temperature-sensitive biomolecules. An optional enclosure protects samples from environmental conditions while allowing full access during a run. Because the enclosure is optional, the same fraction collector can also be used for reverse-phase chromatography applications.
The NGC Fraction Collector runs on ChromLab 5.0 Software, to which users can upgrade for free, no matter what edition they currently use.
Please visit http://www.bio-rad.com/NGCFC for more information about the NGC Fraction Collector.
Bio-Rad, ChromLab, and NGC are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
For more information contact:
Bio-Rad Laboratories, Inc.